NCT06988488: A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Sponsor: Celgene. Phase: PHASE1. Conditions: Multiple Myeloma